Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.

Clear filters

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Oct 26, 2026, 5:16 AM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 217–240 of 380 matching trials from the live ClinicalTrials.gov search.
Filters: Intervention: Antipsychotics Clear all
Completed Phase 3 Interventional Accepts healthy volunteers Results available

A Study to Compare Disease Progression and Modification Following Treatment With Paliperidone Palmitate Long-Acting Injection or Oral Antipsychotics in Participant's With Recent-onset Schizophrenia or Schizophreniform

NCT02431702
View directory record Official record
Conditions
Schizophrenia, Psychotic Disorders
Interventions
Aripiprazole, Haloperidol, Olanzapine, Oral Paliperidone ER, Perphenazine, Quetiapine, Oral Risperidone, Paliperidone Palmitate Injection (PP1M), Paliperidone Palmitate Injection (PP3M)
Drug
Lead sponsor
Janssen Scientific Affairs, LLC
Industry
Eligibility
18 Years to 35 Years
Enrollment
337 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2015 – 2019
U.S. locations
34
States / cities
Little Rock, Arkansas • Garden Grove, California • Lemon Grove, California + 31 more
Source: ClinicalTrials.gov public record
Updated Apr 29, 2025 · Synced Oct 26, 2026, 5:16 AM EDT
Completed Phase 1 Interventional

Characterization of Intramuscular Injections of Risperidone 4 Week Long-acting Injectable (LAI) Formulation in the Buttock of Patients With Schizophrenia

NCT00821600
View directory record Official record
Conditions
Psychotic Disorders, Schizophrenia
Interventions
risperidone IR and LAI formulation
Drug
Lead sponsor
Johnson & Johnson Pharmaceutical Research & Development, L.L.C.
Industry
Eligibility
18 Years to 55 Years
Enrollment
24 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2009
U.S. locations
3
States / cities
Cerritos, California • Santa Ana, California • Atlanta, Georgia
Source: ClinicalTrials.gov public record
Updated May 21, 2014 · Synced Oct 26, 2026, 5:16 AM EDT
Recruiting Phase 2Phase 3 Interventional Accepts healthy volunteers

Managing Agitated Delirium With Neuroleptics and Anti-Epileptics as a Neuroleptic Sparing Strategy

NCT05431595
View directory record Official record
Conditions
Delirium, Epileptics, Neuroleptics
Interventions
Haloperidol, Chlorpromazine, Valproate, Placebo
Drug
Lead sponsor
M.D. Anderson Cancer Center
Other
Eligibility
18 Years and older
Enrollment
42 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2022 – 2027
U.S. locations
1
States / cities
Houston, Texas
Source: ClinicalTrials.gov public record
Updated Nov 18, 2025 · Synced Oct 26, 2026, 5:16 AM EDT
Completed Phase 4 Interventional Results available

Efficacy of Quetiapine in the Treatment of Patients With Schizophrenia and a Comorbid Substance Use Disorder

NCT00156715
View directory record Official record
Conditions
Schizophrenia, Schizoaffective Disorder, Psychotic Disorder, Substance Abuse, Alcohol Abuse
Interventions
Quetiapine
Drug
Lead sponsor
Dartmouth-Hitchcock Medical Center
Other
Eligibility
18 Years to 65 Years
Enrollment
23 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2004 – 2008
U.S. locations
4
States / cities
Augusta, Georgia • Lebanon, New Hampshire • Manchester, New Hampshire
Source: ClinicalTrials.gov public record
Updated Mar 14, 2018 · Synced Oct 26, 2026, 5:16 AM EDT
Completed Phase 4 Interventional Accepts healthy volunteers Results available

Oral Versus Injectable Risperidone for Treating First-Episode Schizophrenia

NCT00330551
View directory record Official record
Conditions
Schizophrenia
Interventions
Oral Risperidone, Risperidone in Long-Acting Injectable Form (Consta)
Drug
Lead sponsor
University of California, Los Angeles
Other
Eligibility
18 Years to 45 Years
Enrollment
126 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2006 – 2012
U.S. locations
1
States / cities
Los Angeles, California
Source: ClinicalTrials.gov public record
Updated Mar 1, 2023 · Synced Oct 26, 2026, 5:16 AM EDT
Completed Phase 4 Interventional Results available

Metformin for Overweight & OBese ChILdren and Adolescents With BDS Treated With SGAs

NCT02515773
View directory record Official record
Conditions
Bipolar Disorder
Interventions
Metformin, healthy lifestyle intervention (LIFE)
Drug · Behavioral
Lead sponsor
Melissa Delbello
Other
Eligibility
8 Years to 19 Years
Enrollment
1,565 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2023
U.S. locations
29
States / cities
Covington, Kentucky • Neptune City, New Jersey • Amityville, New York + 13 more
Source: ClinicalTrials.gov public record
Updated Jan 14, 2025 · Synced Oct 26, 2026, 5:16 AM EDT
Not yet recruiting Not applicable Interventional

Evaluating the Impact of Ketogenic Therapy on Symptom Severity and Metabolic Side Effect Profile Among Individuals Living With Bipolar Disorder in A Rural Southern Catchment Area

NCT07570875
View directory record Official record
Conditions
Bipolar Disorder
Interventions
Ketogenic foodstuffs, Standard of Care Oral antipsychotics, Standard of care long acting injectable medication for bipolar disorder
Dietary Supplement · Other
Lead sponsor
University of Alabama at Birmingham
Other
Eligibility
18 Years and older
Enrollment
100 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2027
U.S. locations
1
States / cities
Montgomery, Alabama
Source: ClinicalTrials.gov public record
Updated Oct 7, 2026 · Synced Oct 26, 2026, 5:16 AM EDT
Completed Not applicable Interventional

Examining Risk Factors for Atypical Antipsychotic Metabolic Side Effects

NCT00815854
View directory record Official record
Conditions
Schizophrenia
Interventions
Folic Acid, Placebo
Dietary Supplement · Other
Lead sponsor
University of Michigan
Other
Eligibility
18 Years to 90 Years
Enrollment
88 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2019
U.S. locations
1
States / cities
Ann Arbor, Michigan
Source: ClinicalTrials.gov public record
Updated Jun 21, 2019 · Synced Oct 26, 2026, 5:16 AM EDT
Recruiting Phase 4 Interventional

Cerebellum-based Imaging Neural Markers for Antipsychotic Response

NCT07483294
View directory record Official record
Conditions
Psychosis; Acute
Interventions
risperidone, aripiprazole
Drug
Lead sponsor
Northwell Health
Other
Eligibility
15 Years to 40 Years
Enrollment
120 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2030
U.S. locations
1
States / cities
Glen Oaks, New York
Source: ClinicalTrials.gov public record
Updated May 26, 2026 · Synced Oct 26, 2026, 5:16 AM EDT
Completed Not applicable Interventional Accepts healthy volunteers

Decision-making and Decision Support Among Emerging Adults With First Episode Psychosis

NCT04373590
View directory record Official record
Conditions
Early Psychosis
Interventions
Decision aid
Behavioral
Lead sponsor
Temple University
Other
Eligibility
18 Years to 25 Years
Enrollment
18 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2019 – 2020
U.S. locations
1
States / cities
Philadelphia, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Feb 15, 2021 · Synced Oct 26, 2026, 5:16 AM EDT
Completed Phase 4 Interventional

Linagliptin and Mesenchymal Stem Cells: A Pilot Study

NCT02442817
View directory record Official record
Conditions
Schizophrenia
Interventions
Linagliptin
Drug
Lead sponsor
University of Nevada, Reno
Other
Eligibility
18 Years to 45 Years
Enrollment
10 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2018
U.S. locations
1
States / cities
Reno, Nevada
Source: ClinicalTrials.gov public record
Updated Nov 9, 2020 · Synced Oct 26, 2026, 5:16 AM EDT
Completed Phase 4 Interventional Accepts healthy volunteers Results available

Impact of Aripiprazole Once Monthly Medications on Changes in Brain Structure and Metabolism

NCT02237417
View directory record Official record
Conditions
Schizophrenia
Interventions
Standard of Care Oral antipsychotics, IM aripiprazole once monthly, No Treatment
Drug · Other
Lead sponsor
University of Utah
Other
Eligibility
18 Years to 35 Years
Enrollment
47 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2014 – 2020
U.S. locations
1
States / cities
Salt Lake City, Utah
Source: ClinicalTrials.gov public record
Updated Mar 14, 2025 · Synced Oct 26, 2026, 5:16 AM EDT
Recruiting Phase 4 Interventional

Clozapine for the Prevention of Violence in Schizophrenia: a Randomized Clinical Trial

NCT05208190
View directory record Official record
Conditions
Schizophrenia, Schizoaffective Disorder
Interventions
Clozapine, treatment as usual
Drug
Lead sponsor
New York State Psychiatric Institute
Other
Eligibility
18 Years to 65 Years
Enrollment
280 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2028
U.S. locations
7
States / cities
Los Angeles, California • Augusta, Georgia • Baltimore, Maryland + 2 more
Source: ClinicalTrials.gov public record
Updated May 4, 2026 · Synced Oct 26, 2026, 5:16 AM EDT
Completed Phase 4 Interventional Results available

Switching to Iloperidone From Other Antipsychotics in Schizophrenia

NCT01207414
View directory record Official record
Conditions
Schizophrenia
Interventions
iloperidone
Drug
Lead sponsor
Novartis
Industry
Eligibility
18 Years to 64 Years
Enrollment
501 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2012
U.S. locations
59
States / cities
Birmingham, Alabama • Cerritos, California • Costa Mesa, California + 46 more
Source: ClinicalTrials.gov public record
Updated Mar 15, 2013 · Synced Oct 26, 2026, 5:16 AM EDT
Completed No phase listed Observational

Relative Effectiveness of Schizophrenia Therapy Study

NCT01245348
View directory record Official record
Conditions
Schizophrenia, Bipolar Disorder
Interventions
SULT4A1-1 genetic test
Genetic
Lead sponsor
Medco Health Solutions, Inc.
Industry
Eligibility
18 Years and older
Enrollment
1,110 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2012
U.S. locations
1
States / cities
Franklin Lakes, New Jersey
Source: ClinicalTrials.gov public record
Updated Feb 25, 2013 · Synced Oct 26, 2026, 5:16 AM EDT
Completed Phase 2 Interventional Results available

Effectiveness of Olanzapine Versus Placebo in Treating Outpatients With Anorexia Nervosa

NCT00692185
View directory record Official record
Conditions
Eating Disorders
Interventions
Olanzapine, Placebo
Drug
Lead sponsor
New York State Psychiatric Institute
Other
Eligibility
16 Years and older
Enrollment
23 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2005 – 2010
U.S. locations
1
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated May 10, 2019 · Synced Oct 26, 2026, 5:16 AM EDT
Completed Phase 2 Interventional

R33: Levetiracetam in Early Psychosis

NCT04317807
View directory record Official record
Conditions
Early Psychosis
Interventions
Levetiracetam Pill, Placebo
Drug · Other
Lead sponsor
NYU Langone Health
Other
Eligibility
16 Years to 40 Years
Enrollment
65 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2025
U.S. locations
1
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated May 29, 2026 · Synced Oct 26, 2026, 5:16 AM EDT
Completed Phase 4 Interventional Results available

Efficacy and Tolerability of Switching to Ziprasidone From Other Antipsychotics

NCT00458211
View directory record Official record
Conditions
Schizophrenia, Schizoaffective Disorder
Interventions
ziprasidone
Drug
Lead sponsor
Bronx Psychiatric Center
Government
Eligibility
18 Years to 65 Years
Enrollment
40 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2005 – 2008
U.S. locations
2
States / cities
Buffalo, New York • The Bronx, New York
Source: ClinicalTrials.gov public record
Updated May 1, 2020 · Synced Oct 26, 2026, 5:16 AM EDT
Completed Phase 4 Interventional Results available

Clozapine for Cannabis Use in Schizophrenia

NCT01639872
View directory record Official record
Conditions
Schizophrenia, Cannabis Abuse, Cannabis Dependence, Dual Diagnosis
Interventions
Clozapine, Risperidone
Drug
Lead sponsor
Dartmouth-Hitchcock Medical Center
Other
Eligibility
18 Years to 55 Years
Enrollment
49 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2017
U.S. locations
9
States / cities
Garden Grove, California • Oakland, California • Miami, Florida + 6 more
Source: ClinicalTrials.gov public record
Updated May 5, 2020 · Synced Oct 26, 2026, 5:16 AM EDT
Completed No phase listed Observational

Adherence in Patients Admitted to a Psychiatric Unit for Acute Psychosis: an Analysis of Serum Levels of Antipsychotics.

NCT01786369
View directory record Official record
Conditions
Schizophrenia, Schizoaffective Disorder, Bipolar Disorder
Interventions
Not listed
Lead sponsor
Northwell Health
Other
Eligibility
18 Years and older
Enrollment
106 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2015
U.S. locations
1
States / cities
Glen Oaks, New York
Source: ClinicalTrials.gov public record
Updated Apr 14, 2015 · Synced Oct 26, 2026, 5:16 AM EDT
Completed No phase listed Observational

Do Self-Report and Physician Impressions of Adherence to Oral Antipsychotic Medication Agree With Objective Data?

NCT00223522
View directory record Official record
Conditions
Schizophrenia, Schizoaffective
Interventions
MEMS caps
Device
Lead sponsor
The University of Texas Health Science Center at San Antonio
Other
Eligibility
18 Years to 55 Years
Enrollment
50 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2004 – 2005
U.S. locations
1
States / cities
San Antonio, Texas
Source: ClinicalTrials.gov public record
Updated Sep 22, 2005 · Synced Oct 26, 2026, 5:16 AM EDT
Completed Phase 2 Interventional Results available

A Study of Tolerability and Efficacy of Cannabidiol on Tremor in Parkinson's Disease

NCT02818777
View directory record Official record
Conditions
Parkinson's Disease
Interventions
cannabidiol
Drug
Lead sponsor
University of Colorado, Denver
Other
Eligibility
40 Years to 80 Years
Enrollment
13 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2017
U.S. locations
1
States / cities
Aurora, Colorado
Source: ClinicalTrials.gov public record
Updated Feb 19, 2019 · Synced Oct 26, 2026, 5:16 AM EDT
Completed Phase 4 Interventional Accepts healthy volunteers

Side Effects of Newer Antipsychotics in Older Adults

NCT00245206
View directory record Official record
Conditions
Schizophrenia, Alzheimer's Disease, Dementia
Interventions
Aripiprazole, Olanzapine, Risperidone
Drug
Lead sponsor
Veterans Medical Research Foundation
Other
Eligibility
40 Years and older
Enrollment
406 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2005 – 2010
U.S. locations
1
States / cities
San Diego, California
Source: ClinicalTrials.gov public record
Updated Dec 17, 2018 · Synced Oct 26, 2026, 5:16 AM EDT
Completed No phase listed Observational

Long-term Antipsychotic Pediatric Safety Trial

NCT03522168
View directory record Official record
Conditions
Weight, Body
Interventions
Risperidone, Aripiprazole
Drug
Lead sponsor
Duke University
Other
Eligibility
3 Years to 18 Years
Enrollment
509 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2023
U.S. locations
37
States / cities
Dothan, Alabama • Phoenix, Arizona • Little Rock, Arkansas + 32 more
Source: ClinicalTrials.gov public record
Updated Apr 7, 2026 · Synced Oct 26, 2026, 5:16 AM EDT